Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01019629 · ClinicalTrials.gov registry record

Fabry Screening Study

A clinical trial of Fabry Disease, sponsored by Baylor Research Institute.

Completed
Registry status
2,724
Enrollment target
1
Study location

NCT01019629 is a study of Fabry Disease that has completed, run by Baylor Research Institute. The registered enrollment target is 2,724 participants, above the 458-participant average among 32 other Fabry Disease trials with a reported enrollment target (495% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01019629, a study of Fabry Disease, has completed, sponsored by Baylor Research Institute.

COMPLETED
Registry status
2,724 participants
Enrollment target
1
Study location

Study Summary

To determine if patients with a deficiency of alpha-galactosidase A are at-risk for cardiac complications that commonly occur in the general population

Conditions Studied

Study Locations (1)

Texas

  • Baylor Institute of Metabolic Disease - Dallas

Trial Details

FieldValue
Enrollment Target 2,724 participants
Start Date 2009-01-29
Est. Completion 2017-12-07

Sponsor

Baylor Research Institute

180 total trials

What the Registry Record Tells You About NCT01019629

The ClinicalTrials.gov registry entry for NCT01019629 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,724 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 458-participant average among 32 other Fabry Disease trials with a reported enrollment target (495% higher). The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Fabry Disease appearing as the primary indexed condition, and to 0 interventions.

NCT01019629 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01019629 about?

NCT01019629 is a clinical study titled "Fabry Screening Study". To determine if patients with a deficiency of alpha-galactosidase A are at-risk for cardiac complications that commonly occur in the general population

What is the current status of trial NCT01019629?

This trial is currently completed. The enrollment target is 2,724 participants. The study started on 2009-01-29. Estimated completion is 2017-12-07.

What conditions does trial NCT01019629 study?

This clinical trial studies the following conditions: Fabry Disease.

Who is sponsoring clinical trial NCT01019629?

This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01019629 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fabry Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.